GHK-Cu and GLP-1 hair loss: separating signal from hype

What did @kimconstableofficial actually say?

The creator describes using a copper peptide (GHK-Cu) subcutaneously for ten weeks and credits it with rapid hair and nail growth. She then pivots to GLP-1-related hair loss, arguing it happens because "your body views hair as non-essential" and that it sheds hair when calories drop too low. Her prescription: don't dose too high, don't slash calories, and use copper peptide if you want hair to grow.

The video is light on evidence and heavy on personal observation. She can't say the peptide's name on TikTok, she notes, which is itself a signal that what's being discussed sits in legally and clinically complicated territory. Her hair and nail observations are entirely anecdotal, with no baseline photos, no control, and no way to rule out other variables across ten weeks of life.

Does the science back this up?

On GHK-Cu, the early data is genuinely interesting, but it is nowhere near proof of the dramatic effects she describes. On GLP-1 hair loss, the mechanism she describes is real, but her framing oversimplifies it to the point of being misleading.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) has been studied in the context of wound healing and hair follicle stimulation. Pickart et al. (2015, Journal of Aging Science) documented GHK-Cu's role in upregulating genes associated with tissue repair. Kang et al. (2014, Archives of Dermatological Research) found that topical copper peptides increased hair follicle size in mice. These are early-stage findings, mostly in vitro or animal models. Human trial data on subcutaneous GHK-Cu for hair specifically is essentially nonexistent in peer-reviewed literature. The nail growth claim has no published evidence base at all.

On GLP-1 hair loss, the phenomenon is called telogen effluvium, and it is documented. Guarente et al. (2023, Obesity) noted hair loss as an adverse effect in semaglutide trial participants. But the cause is not simply "too high a dose" or "too low calories." It is a physiological stress response triggered by rapid weight loss itself, regardless of how it is achieved.

What did they get wrong (or right)?

She gets one thing broadly right: caloric restriction and physiological stress can accelerate telogen effluvium in people on GLP-1 medications. That part is consistent with what dermatologists and obesity medicine physicians actually observe.

She gets the cause wrong by oversimplifying it. Telogen effluvium on GLP-1s is not purely a dosing problem you can engineer away. It is largely a consequence of rapid weight loss, which is often the intended outcome of the medication. Telling viewers "don't slash your calories and your hair won't fall out" is functionally telling them the drug's main mechanism of action is the problem, without giving them a useful clinical path forward.

Her GHK-Cu claims are the bigger issue. Describing dramatic, visible hair regrowth after ten weeks of subcutaneous use, citing personal observation only, and then recommending viewers "use copper if you want it to grow" is not fact, it is marketing dressed as testimony. The peptide may have real biological activity, but the leap from "interesting mechanistic data" to "I can see millions of tiny baby hairs" is not one the evidence supports.

What should you actually know?

Telogen effluvium affects roughly 25-50% of people who lose weight rapidly, according to a 2022 review by Starace et al. in Dermatology and Therapy. It typically begins two to four months after a significant physiological stressor and resolves on its own in most cases. Adequate protein intake (commonly cited at 1.2-1.6g per kg of body weight in clinical obesity guidelines) does appear to reduce severity. This is better, more actionable advice than "don't dose too high."

On GHK-Cu: it is not FDA-approved for hair regrowth. It is not cleared for subcutaneous self-administration. Most clinical interest in GHK-Cu involves topical formulations studied in dermatology, not injection protocols. Anyone considering peptide therapy should be doing so under supervision of a licensed provider who can assess safety, dosing context, and individual risk factors. A TikTok testimonial with no before-and-after data is not a clinical rationale.

• If you are losing hair on a GLP-1 medication, speak to your prescriber before adjusting your dose based on social media advice.
• Protein adequacy and overall nutritional sufficiency matter for hair cycling, but they do not guarantee you will avoid telogen effluvium during rapid weight loss.
• GHK-Cu has early-stage mechanistic interest in wound healing and hair follicle biology, but human evidence for subcutaneous use is not established.